Carbogen

Summary

Carbogen (CHEMBL4297716) is a phase-3 clinical-stage unknown; indicated across 3 conditions.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297716
Name	Carbogen
Type	Unknown
Max phase	3

Also known as: Carbogen, Meduna’s mixture, CARBOGEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00033436	PHASE3	COMPLETED	Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
NCT01370044	PHASE2/PHASE3	TERMINATED	Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures
NCT04839224	PHASE3	TERMINATED	Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)
NCT01123005	PHASE1	TERMINATED	Imaging and Biomarkers of Hypoxia in Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).